[Hurler syndrome: early diagnosis and treatment]

S Leroux1, J-B Muller1, E Boutaric1

  • 1Service de néonatologie, hôpital Mère-Enfant, CHU de Nantes, , 38, boulevard Jean-Monnet, 44000 Nantes, France.

Insights

Hurler syndrome (MPS I) is a rare genetic disorder. Early diagnosis and treatment with enzyme replacement and stem cell therapy can stabilize symptoms and preserve cognitive development in infants.

Area of Science:

  • Genetics and rare diseases
  • Lysosomal storage disorders
  • Pediatric medicine

Background:

  • Hurler syndrome (Mucopolysaccharidosis type I) is a severe lysosomal storage disease caused by alpha-L-iduronidase deficiency.
  • Glycosaminoglycan accumulation leads to progressive multi-organ dysfunction.
  • MPS I incidence is approximately 1-2 per 100,000 live births.

Observation:

  • A 3-week-old infant presented with feeding difficulties, coarse facial features, hypotonia, and airway obstruction.
  • Clinical signs and biochemical tests confirmed MPS I, including elevated urinary GAGs and absent alpha-L-iduronidase activity.
  • Genetic analysis revealed homozygosity for the p.W402X mutation in the IDUA gene.

Findings:

  • The infant experienced progressive symptoms including skeletal deformities, glaucoma, and dilated cardiomyopathy.
  • Enzyme replacement therapy (ERT) with laronidase at 5 months stabilized cardiac function and reduced organomegaly.
  • Hematopoietic stem cell transplantation (HSCT) at 11 months preserved cognitive development.

Implications:

  • This case highlights the critical role of early diagnosis in managing Hurler syndrome.
  • Combined ERT and HSCT can effectively manage severe MPS I manifestations.
  • Timely intervention is key to preventing irreversible organ damage and preserving neurodevelopment.

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
409
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544